key: cord-0739384-thnp3zip
authors: Rudnicka, Lidia; Goldust, Mohamad; Glowacka, Paulina; Sikora, Mariusz; Sar-Pomian, Marta; Rakowska, Adriana; Samochocki, Zbigniew; Olszewska, Malgorzata
title: Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern.
date: 2020-05-04
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.04.153
sha: c3a7413f3b94f16297c1f29e7370fa3e2a8ae30d
doc_id: 739384
cord_uid: thnp3zip

nan

The rapid dissemination of the novel coronavirus SARS-CoV2 and COVID-19 pandemic raised concerns related to possible risks associated with the immunosuppressive treatment of autoimmune diseases. 1 The effect of cyclosporine on coronaviruses other than the new SARS-CoV2 has been extensively studied. The attention was especially paid to two life-threatening coronaviruses in humans, SARS-CoV and MERS-CoV. The data showed that cyclosporine reduced MERS-CoV and SARS-COV replication in vitro. 5 A similar inhibiting effect was observed in case of other coronaviruses, including HCoV-229E, TGEV, FCoV, PEDV and MHV. 5 Promising in vitro results led some authors to the speculation that cyclosporin may be an interesting treatment option for severe acute respiratory syndrome (SARS). 6 No literature data are available on the effect of cyclosporine on the SARS-CoV2, which causes COVID-19, but available data allow us to hypothesize that patients who receive cyclosporine treatment for dermatological autoimmune diseases may benefit from its antiviral activity. They are probably at a lower risk of developing severe symptoms related to COVID-19 compared to patients who receive other treatments for their conditions. An open question remains whether the antiviral activity of cyclosporine may impair the development of immunity to coronaviruses and, in consequence, increase vulnerability to future infections.

Priorities for Global Health Community in COVID

The coronavirus (COVID-19) epidemic and patient safety

Prevalence of Past and Reactivated Viral Infections and Efficacy of Cyclosporine A as Monotherapy or in Combination in Patients with Psoriatic Arthritis-Synergy Study: A Longitudinal Observational Study

Novel activities of safe-in-human broadspectrum antiviral agents

Cyclophilins and cyclophilin inhibitors in nidovirus replication

Cyclosporine has a potential role in the treatment of SARS